Traws Pharma, Inc. Current Income Tax Expense (Benefit)
Traws Pharma, Inc. (TRAW) reported Current Income Tax Expense (Benefit) of $4.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-21.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2022-03-21
- Traws Pharma, Inc. current income tax expense (benefit) for fiscal 2020 was $4.00K, a 60.00% decline from fiscal 2019.
- Traws Pharma, Inc. current income tax expense (benefit) for fiscal 2019 was $10.00K, a 23.08% decline from fiscal 2018.
- Traws Pharma, Inc. current income tax expense (benefit) for fiscal 2018 was $13.00K, a 0.00% change from fiscal 2017.
- Traws Pharma, Inc. current income tax expense (benefit) for fiscal 2017 was $13.00K, a 7.14% decline from fiscal 2016.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2020-12-31 | $4.00K 10-K · filed 2022-03-21 |
| 2019-12-31 | $10.00K 10-K · filed 2021-03-18 |
| 2018-12-31 | $13.00K 10-K · filed 2020-03-27 |
| 2017-12-31 | $13.00K 10-K · filed 2019-04-01 |
| 2016-12-31 | $14.00K 10-K · filed 2018-03-16 |
| 2015-12-31 | $16.00K 10-K · filed 2017-03-29 |
| 2014-12-31 | $19.00K 10-K · filed 2016-03-28 |
| 2013-12-31 | $435.00K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |